TLSI

TriSalus Life Sciences, Inc. (TLSI) Business Model Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Model

The company generates revenue, but TTM price-to-sales of 6.60 suggests the market is still assigning a meaningful growth premium.

Revenue per share is 0.77, indicating a relatively small current revenue base.

Profitability

Gross margin is very strong at 85.8%, showing the core product/service economics are attractive.

However, EBITDA margin (-48.1%), operating margin (-67.7%), and net margin (-62.6%) are deeply negative on a TTM basis.

Capital Efficiency

Asset turnover of 0.72 and fixed-asset turnover of 17.1 indicate the asset base is being used to generate sales.

Current ratio of 5.35 and cash ratio of 4.14 show strong short-term liquidity.

Balance Sheet

Liquidity is strong, supported by a current ratio of 5.35 and cash per share of 0.79.

Debt-to-market-cap is only 0.11, suggesting leverage is not overwhelming relative to equity value.

Growth Durability

The business still has a viable operating footprint, with gross profit margin remaining high despite losses.

The market is valuing the company at a premium sales multiple, implying some expectation of future durability.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on TriSalus Life Sciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →